Life After s Loss: Impact of Hepatitis B s Antigen Loss on Future Patient Outcomes
Daniel Q Huang 1 2 , Seng Gee Lim 1 2
Affiliations
Affiliations
1
Division of Gastroenterology and Hepatology Department of Medicine National University Hospital Singapore.
2
Department of Medicine Yong Loo Lin School of Medicine National University of Singapore Singapore.
PMID: 33489099 PMCID: PMC7805298 DOI: 10.1002/cld.983
Chronic hepatitis B (CHB) affects an estimated 257 mil-lion people worldwide and contributed to 887,000 deaths in 2015 alone.1 Hepatitis B s antigen (HBsAg) is present in 3.6% of the world’s population,2 and 12% to 20% of patients with CHB go on to experience development of liver cirrhosis. Among the individuals with cirrhosis, 20% to 23% experience development of liver decompensation, and 6% to 15% experience development of hepatocellu-lar carcinoma (HCC).3The presence of covalently closed circular DNA and hepatitis B virus (HBV) integration into DNA makes complete removal of HBV unlikely with current antiviral strategies. An international workshop involving European Association for the Study of the Liver and American Association for the Study of Liver Diseases concluded that functional cure, or HBsAg loss 6 months after stopping therapy, is an accept-able goal of therapy.作者: StephenW 时间: 2021-1-26 15:58